Athira Pharma Secures $236 Million Financing and Exclusive Rights to Lasofoxifene for ESR1-Mutant Metastatic Breast Cancer
核心洞察
Athira Pharma acquired exclusive global licensing rights to lasofoxifene, a selective estrogen receptor (搜索) modulator in Phase 3 development for ESR1 (搜索)-mutant metastatic breast cancer (搜索).
The company secured $236 million in total financing, including $90 million upfront and up to $146 million through warrants, to support development through regulatory milestones.
Lasofoxifene demonstrated promising Phase 2 results with 13 months progression-free survival in heavily pretreated patients and targets approximately 40% of breast cancer patients who develop ESR1 (搜索) mutations.
Athira Pharma announced a transformative licensing agreement and financing package that positions the company to advance lasofoxifene, a promising selective estrogen receptor (搜索) modulator (SERM), through Phase 3 development for metastatic breast cancer (搜索). The clinical-stage biopharmaceutical company secured exclusive global rights to the drug candidate from Sermonix Pharmaceuticals (搜索), along with $236 million in total financing to support development through key regulatory milestones.
Strategic Licensing Agreement and Financing Structure
The licensing agreement grants Athira exclusive global rights to develop and commercialize lasofoxifene, excluding Asia and certain Middle Eastern countries. As part of the transaction, Athira will issue Sermonix a pre-funded warrant to purchase approximately 5.5 million shares of common stock at an exercise price of $0.001 per share. Additional milestone payments of up to $100 million may be triggered based on commercialization achievements and annual net sales targets, with royalty payments ranging from sub-single digit to low-single digit percentages.
The financing package includes $90 million in upfront private placement funding, co-led by Commodore Capital (搜索), Perceptive Advisors (搜索), and TCGX (搜索). Additional participants include ADAR1, Blackstone Multi-Asset Investing, Kalehua Capital, Ligand Pharmaceuticals, New Enterprise Associates (NEA), Spruce Street Capital, and 9vc. Warrants accompanying the financing could provide up to an additional $146 million if exercised, bringing total potential funding to $236 million.
"Today marks a defining moment for our company," said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. "This program provides a near-term opportunity to generate pivotal data necessary for the approval of lasofoxifene and to establish it as the new standard of care to treat ESR1-mutant breast cancer (搜索) in patients who have progressed on aromatase inhibitors and prior CDK4/6 (搜索) inhibitors."
Clinical Development Program and Market Opportunity
The ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) is evaluating lasofoxifene in combination with the CDK4/6 (搜索) inhibitor abemaciclib for estrogen receptor (搜索)-positive (ER+), HER2-negative, ESR1 (搜索)-mutated metastatic breast cancer (搜索). The trial is more than 50% enrolled with topline data expected in mid-2027.
Lasofoxifene targets a genetically defined patient population with significant unmet medical need. Approximately 40% of breast cancer patients develop ESR1 (搜索) mutations and have limited treatment options following progression on aromatase inhibitors and CDK4/6 (搜索) inhibitors, according to Cariad Chester, Managing Partner at TCGX (搜索).
The metastatic breast cancer (搜索) treatment market represents a substantial commercial opportunity. In the United States, approximately 260,000 cases (5.6%) of the 4.65 million new female breast cancer cases are diagnosed as distant metastatic stage at initial diagnosis. The global metastatic breast cancer treatment market was valued at $17.1 billion in 2021 and is projected to reach $41.7 billion by 2030, representing a compound annual growth rate of approximately 10.4%.
Compelling Phase 2 Clinical Data
Lasofoxifene's development is supported by positive results from two Phase 2 studies. The ELAINE-1 randomized trial compared lasofoxifene to fulvestrant and demonstrated superior outcomes for lasofoxifene, including longer median progression-free survival (5.6 vs. 3.7 months), higher objective response rates (13.3% vs. 2.9%), and a durable complete response lasting more than 2.5 years. Patients also reported quality-of-life benefits and the treatment was well tolerated.
The ELAINE-2 open-label study evaluated lasofoxifene in combination with abemaciclib in heavily pretreated patients. Results showed a median progression-free survival of approximately 13 months, an objective response rate of 56%, and a clinical benefit rate of 65.5%. The combination was generally well tolerated, with most adverse events being low grade.
"In the ELAINE-2 clinical trial, lasofoxifene demonstrated the potential to provide meaningful combination efficacy with 13 months of progression-free survival in heavily pre-treated second- and third-line ESR1 (搜索)-mutated metastatic breast cancer (搜索) patients," noted David Portman, M.D., Chief Executive Officer of Sermonix.
Unique Mechanism of Action
Lasofoxifene is a novel, nonsteroidal selective estrogen receptor (搜索) modulator with a unique binding profile designed to confer potent activity against both wild-type and mutant estrogen receptors, including clinically significant ESR1 (搜索) mutations commonly associated with resistance to endocrine therapy in metastatic breast cancer (搜索).
The drug's tissue-selective SERM profile may allow for preservation of estrogen function in non-breast tissue, potentially providing tolerability benefits and bone protection while maintaining quality of life for patients. This differentiated profile positions lasofoxifene as a potential preferred endocrine therapy for metastatic breast cancer (搜索) patients with ESR1 (搜索) mutations.
Financial Runway and Development Timeline
Athira anticipates the upfront financing will support lasofoxifene development through topline data readout and key regulatory milestones, providing sufficient capital runway into 2028. The company plans to use proceeds to fund lasofoxifene development for treatment-resistant metastatic breast cancer (搜索), as well as other pipeline assets including ATH-1105 for amyotrophic lateral sclerosis (搜索) (ALS (搜索)).
The private placement is expected to close on or about December 23, 2025, subject to customary closing conditions. Cantor is serving as exclusive financial advisor to Athira for the license transaction and sole placement agent for the private placement.
"The scientific and clinical data supporting lasofoxifene are compelling, and we are confident in Athira's leadership to drive the Company's next chapter with clarity, urgency, and excellence," stated Joseph Edelman, Founder and CEO of Perceptive Advisors (搜索).